<DOC>
	<DOCNO>NCT00002481</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Bone marrow transplantation may allow doctor give high dos radiation therapy chemotherapy kill cancer cell . PURPOSE : Phase II trial study effectiveness high-dose etoposide cyclophosphamide plus total-body irradiation follow bone marrow transplantation treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Plus Bone Marrow Transplantation Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity activity cyclophosphamide , etoposide , total body irradiation , autologous bone marrow transplantation patient relapse refractory non-Hodgkin 's lymphoma . II . Determine feasibility pretransplantation cytoreduction regimen high-dose cytarabine , cisplatin , dexamethasone patient population . III . Determine feasibility posttransplantation radiotherapy give sit residual disease ( involved-field `` boost '' irradiation ) patient population . OUTLINE : Patients stratify disease status ( refractory v relapse ) . Autologous bone marrow harvest cytoreduction involve field radiotherapy ( IFRT ) . Patients marrow involvement achieve marrow complete response cytoreduction undergo harvest bone marrow IFRT . Patients receive cytoreduction comprise high-dose cytarabine IV 1 hour every 12 hour , cisplatin IV 10 hour , dexamethasone three time daily day 1 2 . At 3 week , second course administer tumor reduction least 25 % absence unacceptable toxicity . Patients involve site 2 cm great diameter evaluation previously unirradiated active disease site , least 90 % treated IFRT , undergo IFRT 5 day week 2 week begin cytoreduction 3-5 week harvest bone marrow . Within 10 day completion IFRT , patient receive etoposide IV 26 hour begin day -7 , cyclophosphamide IV 2 hour day -6 -4 , total body irradiation twice daily day -3 -2 day -1 . Bone marrow reinfused day 0 . Eligible patient residual disease 3 month transplantation undergo involved field `` boost '' irradiation sit residual disease . PROJECTED ACCRUAL : Approximately 50 patient ( 25 per stratum ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven unequivocal radiologic evidence nonHodgkin 's lymphoma relapse refractory firstline chemotherapy Unequivocal radiologic evidence relapse define presence enlarge ( least 2 cm diameter ) lymph node CT scan lymphangiogram Biopsy accessible lymph node confirm relapse encourage Low , intermediate , highgrade disease Normal bilateral bone marrow biopsy time bone marrow collection require ( cellularity least 20 % histologic evidence tumor ) History marrow involvement allow present marrow histologically normal No disease progression previously irradiate site A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 16 Performance status : CALGB 02 Karnofsky 70100 % Life expectancy : More 2 month Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 3 time normal SGOT SGPT less 3 time normal Alkaline phosphatase less 3 time normal Hepatitis B surface antigen negative Renal : Creatinine normal Creatinine clearance least 60 mL/min Cardiovascular : Cardiac ejection fraction normal MUGA scan No uncontrolled severe cardiovascular disease , include follow : Myocardial infarction within past 6 month Congestive heart failure Symptomatic angina ( despite optimal medical management ) Lifethreatening arrhythmia hypertension Pulmonary : Pulmonary function test ( DLCO spirometry ) great 60 % predict Other : HIV negative No serious organ dysfunction ( unless cause lymphoma ) No active bacterial , viral , fungal infection No active peptic ulcer disease No uncontrolled diabetes mellitus No malignancy except curatively treat carcinoma situ cervix basal cell squamous cell skin cancer No serious medical psychiatric illness would preclude study Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior nitrosourea allow cumulative dose 600 mg/m2 Prior bleomycin allow cumulative dose 300 units/m2 Prior doxorubicin allow cumulative dose 450 mg/m2 No prior highdose etoposide ( 1,800 mg/m2 ) No prior highdose cyclophosphamide ( 100 mg/kg ) No chemotherapy within 4 week ( melphalan , nitrosourea , mitomycin within 6 week ) prior bone marrow collection No prior salvage therapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy liver lung Prior radiotherapy allow dos exceed follow limit : 1,400 cGy mediastinum 1,400 cGy whole abdomen 4,000 cGy CNS Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>